| endorphin |
drug |
4 |
2 |
endogenous MOR ligand |
| energy expenditure |
phenotype |
3 |
3 |
EE |
| energy homeostasis |
phenotype |
8 |
7 |
metabolic balance |
| energy intake |
phenotype |
4 |
1 |
caloric intake, energy intake, food intake |
| England |
cohort |
2 |
— |
England population, England survey |
| enhancement motives |
phenotype |
2 |
1 |
enhancement motivation |
| enhancer |
drug |
9 |
3 |
active enhancer |
| ENIGMA |
cohort |
8 |
4 |
ENIGMA consortium, ENIGMA imputation protocols |
| ENIGMA consortium |
cohort |
4 |
— |
ENIGMA |
| ENIGMA-OCD working group |
cohort |
2 |
2 |
|
| enjoyment |
phenotype |
2 |
2 |
|
| enkephalin |
drug |
6 |
4 |
Methionine-enkephalin |
| Ensembl |
drug |
5 |
4 |
|
| entacapone |
drug |
2 |
1 |
|
| ENU |
drug |
2 |
2 |
N-ethyl-N-nitrosourea |
| environment |
drug |
4 |
3 |
environment, environmental factors |
| environmental enrichment |
drug |
2 |
2 |
|
| environmental exposures |
drug |
6 |
7 |
environmental background, environmental exposure, environmental exposures, environmental factors |
| environmental factors |
drug |
20 |
15 |
common environmental factors, environmental factor, environmental risk factor, environmental risk factors |
| environmental influences |
phenotype |
6 |
3 |
environmental factors, environmental mechanisms |
